Table 1.
Detailed information of the included studies
| Study and year | Type | Country | Company | Medicine | Intervention | Follow-up, weeks | Group | Subgroup§ | Outcomes‡ |
|---|---|---|---|---|---|---|---|---|---|
| Fleischmann 2019 [51] | RCT | USA | AbbVie Inc | ABT981(IL-1 antibody) | SC, once every 2 weeks, lasting for 50 weeks | 52 |
25 mg 100 mg 200 mg |
Subgroup 1 Subgroup 2 Subgroup 3 |
①②⑥ |
| Cohen 2011 [52] | RCT | USA | Amgen Inc |
AMG 108 (IL-1 Ras) |
SC, once every 4 weeks, lasting for 12 weeks IV, once every 4 weeks, lasting for 12 weeks SC, once every 4 weeks, lasting for 12 weeks |
12 |
75 mg 300 mg 100 mg 300 mg 300 mg |
Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4 Subgroup5 |
⑥ |
| Baltzer 2009 [53] | Multicentre enter RCT | Germany | NA |
Orthokine† (IL-1 Ras) |
IA, twice a week, lasting for 3 weeks | 26 | NA | Subgroup 1 | ①②⑤⑥ |
| Yang 2008 [54] | RCT | Netherlands | NA |
Orthokine† (IL-1 Ras) |
IA on days 0, 3, 7, 10, 14 and 21 | 48 | NA | Subgroup 1 | ③④⑤ |
| Wang 2017 [55] | RCT | USA | AbbVie Inc |
ABT-981 (IL-1 antibody) |
SC, once every 1 week, lasting for 8 weeks SC, once every 4 weeks, lasting for 12 weeks |
16.7 18.1 |
0.3 mg/kg 1 mg/kg 3 mg/kg 3 mg/kg |
Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4 |
⑥ |
| Chevalier 2009 [56] | Multicentre enter RCT | France | Amgen Inc |
Anakinra (IL-1 Ras) |
Single IA | 12 |
50 mg 150 mg |
Subgroup 1 Subgroup 2 |
⑤⑥ |
| Kosloski 2016 [57] | RCT | USA | AbbVie Inc | ABT-981(IL-1 antibody) |
SC, once every 2 weeks, lasting for 8 weeks SC, once every 4 weeks, lasting for 12 weeks |
18 |
0.3 mg/kg 1 mg/kg 3 mg/kg 3 mg/kg |
Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4 |
⑥ |
| NCT01160822 2012[58] | RCT | USA | Novartis Inc |
Canakinumab (IL-1 antibody) |
Single IA Single IA of canakinumab + oral placebo twice a day (control group: placebo + placebo), lasting for 12 weeks |
18 |
150 mg 300 mg 600 mg 600 mg Canakinumab + placebo |
Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4 |
⑥ |
| Brahmachari 2009 [59] | RCT | India | NA | Diacerein(IL-1 inhibitor) | Oral, once a day for the first 10 days, 50 mg after meals, lasting for 8 weeks | 12 | NA | Subgroup 1 | ②⑤⑥ |
| Pelletier 2000 [60] | Multicentre enter RCT | France | Les Laboratoires Negma | Diacerein(IL-1 inhibitor) | Oral twice a day for 16 weeks | 12 |
50 mg 100 mg 150 mg |
Subgroup 1 Subgroup 2 Subgroup 3 |
①②⑤⑥ |
| Pham 2004 [61] | Multicentre enter RCT | France | NA | Diacerein(IL-1 inhibitor) | Oral twice a day for 12 weeks | 48 | NA | Subgroup 1 | ⑤⑥ |
| Pavelka 2007 [62] | Multicentre enter RCT | Czech | TRB Chemedica and Glynn Brothers Chemicals | Diacerein(IL-1 inhibitor) | Oral twice a day for 12 weeks | 24 | NA | Subgroup 1 | ②⑥ |
*RCT randomized controlled trial; SC subcutaneous injection; IV intravenous injection; IA intra-articular injection; WOMAC Western Ontario and McMaster Universities Osteoarthritis Index; KOOS Knee Injury and Osteoarthritis Outcome Score; VAS visual analogue scale; and NA not available
Universities Osteoarthritis Index
†Orthokine: Orthokine is the trade name of autologous-conditioned serum (ACS)
‡Data extraction results of outcomes: ① WOMAC pain score; ② WOMAC function score; ③ KOOS pain score; ④ KOOS function score; ⑤ VAS score; and ⑥ adverse events
§Due to the limited number of studies, we named and grouped the research projects in different ways according to the original research
Baseline characteristics of studies included in the meta-analysis